查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1611687

非鸦片类疼痛治疗市场规模、份额和趋势分析报告：按药物类别、疼痛、给药途径、通路、地区和细分市场预测，2025-2030

Non-opioid Pain Treatment Market Size, Share & Trends Analysis Report By Drug Class, By Pain, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

非阿片类疼痛治疗市场的成长与趋势

Grand View Research, Inc.最新报告显示，预计到2030年，全球非鸦片类疼痛治疗市场规模将达到703亿美元，2025年至2030年复合年增长率为7.69%。

这种增长是由发炎性疾病的日益普及以及新型非鸦片类镇痛药的强大产品平臺所推动的。根据美国疾病管制与预防中心 (CDC) 的数据，美国约有 3,250 万人患有骨关节炎，根据美国的数据，美国约有 320 万人患有某种形式的脊椎关节病变。

各国政府和非营利组织正在努力推广使用更安全的鸦片类药物替代品，例如非类固醇抗发炎药，以满足对止痛药物不断增长的需求。例如，2022年2月，美国FDA发布指南草案，建议製药公司开发NSAIDs来治疗持续30天的急性疼痛。该倡议是政府 HHS过量摄取预防策略的一部分，该策略的重点是预防、减少、治疗阿片类药物过量摄取并从中恢復。预计此类措施将在预测期内推动对非类固醇抗发炎药的需求。

市场主要参与企业正在积极开发创新技术，以满足对非类固醇抗发炎药物用于疼痛管理不断增长的需求。例如，2021 年 6 月，亚利桑那大学开发了一种催产素类似物，用于治疗患病患者。它是一种生物可利用的非鸦片类镇痛药，可以透过吸入给药。此类创新产品的开发预计将推动非阿片类镇痛治疗市场的成长。

2022年9月，美国FDA建议怀孕20週时避免使用非鸦片类止痛治疗，因为这会增加胎儿肾臟损伤的风险。这些政府措施可能会限制非类固醇抗发炎药的配方，从而限制非鸦片类镇痛药市场的成长。

公司正在采用新产品开发、商业发布和合作伙伴关係等策略来提高非鸦片类镇痛药的渗透率。例如，2022 年 3 月，Vertex Pharmaceuticals 宣布一项 2 期临床试验的积极结果表明，非阿片类药物锭剂可显着减轻术后急性疼痛。成功的临床实验和随后的产品核准预计将在预测期内推动非阿片类镇痛治疗市场的成长。

该市场竞争激烈，参与企业数量众多，预计预测期内市场竞争将处于高水准。生产非专利抗发炎药仿製药的主要企业包括 GSK plc.、Sun Pharmaceutical Industries Ltd.、Novartis AG、Teva Pharmaceutical Industries Ltd.、Viatris Inc. 和 Johnson & Johnson Services, Inc.。

非阿片类疼痛治疗市场的报告亮点

  • 2024年，NSAIDs细分市场占据最大的市场占有率，并且由于近年来对疼痛治疗和多种NSAIDs商业化的高需求，预计在预测期内将保持其主导地位。
  • 到 2024 年，慢性疼痛比例将最高。产品核可增加、慢性疼痛的高盛行率以及推出创新非类固醇消炎剂产品的高研发倡议等因素导致了这一优势。
  • 按给药途径类型划分，口服非类固醇抗发炎药产品在 2024 年占据最高份额，因为口服非类固醇抗发炎药产品易于给药且在市场上广泛使用。
  • 从分销管道来看，零售药局预计将在 2024 年以 54.39% 的份额占据市场主导地位。这一优点是由于有大量非非专利非类固醇消炎剂可供选择，并且患者可以透过强大的零售药房网路轻鬆获得这些药物。
  • 由于新兴国家非类固醇抗发炎药产品渗透率的提高、可支配收入的增加以及发炎性疾病的盛行率较高，预计亚太地区将在预测期内经历最快的增长。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章非鸦片类镇痛治疗市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 非阿片类疼痛治疗市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
  • 价格分析

第四章 非鸦片类镇痛治疗市场：依药物类别估计与趋势分析

  • 细分仪表板
  • 全球非鸦片类镇痛治疗市场：药物类别变化分析
  • 按药品和类别分類的收益
  • NSAID
    • 非选择性非类固醇抗发炎药
    • 选择性COX-2抑制剂
  • 乙酰胺酚
  • 局部麻醉剂
  • 其他的

第五章 非鸦片类镇痛治疗市场：依疼痛类别估计与趋势分析

  • 细分仪表板
  • 全球非鸦片类镇痛治疗市场：疼痛波动分析
  • 痛苦，收益
  • 术后疼痛
  • 癌症痛
  • 慢性疼痛
  • 其他疼痛

第六章 非鸦片类镇痛治疗市场：依给药途径的估计与趋势分析

  • 细分仪表板
  • 全球非鸦片类镇痛治疗市场：给药途径变化分析
  • 按管理途径分類的收益
  • 口服
  • 局部的
  • 注射
  • 其他的

第七章 非鸦片类镇痛治疗市场：按分销管道估计和趋势分析

  • 细分仪表板
  • 全球非鸦片类镇痛治疗市场：通路波动分析
  • 按分销管道分類的收益
  • 医院药房
  • 零售药房
  • 网路药房

第八章非鸦片类镇痛治疗市场：按药物类别、镇痛、给药途径和分销管道分類的区域估计和趋势分析

  • 区域仪表板
  • 2018-2030年市场规模及预测趋势分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第9章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
    • 2024年主要企业市场占有率分析
    • Novartis AG
    • Teva Pharmaceutical Industries Limited
    • Sun Pharmaceutical Industries Ltd
    • GSK plc.
    • Pfizer Inc.
    • Perrigo Company plc.
    • LNK International, Inc.
    • Cipla Inc.
    • Johnson & Johnson Services, Inc.
    • Pacira Pharmaceuticals, Inc.
    • Pierrel
Product Code: GVR-4-68039-983-1

Non-opioid Pain Treatment Market Growth & Trends:

The global non-opioid pain treatment market size is expected to reach USD 70.30 billion by 2030, registering a CAGR of 7.69% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth can be attributed to an increase in the prevalence of inflammatory diseases coupled with the robust product pipeline of novel non-opioid analgesics. According to the Centers for Disease Control and Prevention (CDC), around 32.5 million people are living with osteoarthritis condition in the U.S. In addition, according to the Spondylitis Association of America, about 3.2 million adult people in the U.S. have some form of Spondyloarthritis.

Initiatives are undertaken by government & nonprofit organizations to promote the usage of safer alternatives to opioids such as NSAIDs to address the increasing demand for pain relieving medicines. For instance, in February 2022, the U.S.FDA issued draft guidelines to provide recommendations to pharmaceutical companies for developing NSAIDs for the treatment of acute pain lasting for 30 days. This initiative was a part of the government's "HHS Overdose Prevention Strategy" which focuses on the prevention, reduction, treatment, and recovery of patients from an opioid overdose. Such an initiative is projected to fuel demand for NSAID drugs over the forecast period.

Key market players are aggressively developing innovative techniques to meet the growing demand for NSAIDs for the management of pain. For instance, in June 2021, the University of Arizona developed oxytocin analogs for the treatment of patients suffering from. It is a bioavailable non-opioid pain relief product with the potential for inhaled administration. The development of such an innovative product is anticipated to drive non-opioid analgesics treatment market growth.

In September 2022, the U.S. FDA recommended avoiding non-opioid analgesics treatment in pregnancy at 20 weeks due to the high chances of kidney problems in unborn babies. Such initiatives from governments may limit the prescription of NSAIDs, thereby, restraining non-opioid pain treatment market growth.

Companies are adopting strategies such as new product development, launches, and partnerships to increase the penetration of non-opioid analgesic products. For instance, in March 2022, Vertex Pharmaceuticals announced positive results of its phase 2 clinical trial non-opioid pill that showed a significant reduction in post-operative acute pain. Successful completion of trial and subsequent approval of products is anticipated to drive non-opioid analgesics treatment market growth during the forecast period.

The market is highly competitive and the competition in the market is expected to be high during the forecast period due to the presence of a large number of players. Key companies manufacturing generic NSAID products include GSK plc., Sun Pharmaceutical Industries Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Johnson & Johnson Services, Inc., amongst others.

Non-opioid Pain Treatment Market Report Highlights:

  • In 2024, the NSAIDs segment accounted for the largest market share and is anticipated to maintain its dominance over the forecast period owing to the high demand for pain treatment and the commercialization of multiple NSAIDs in recent years
  • Chronic pain was the accounted for highest share in 2024. Factors such as increasing product approvals, the high incidence rate of chronic pain, and high R&D initiatives for launching innovative NSAIDs products are leading to its dominance
  • Based on route of administration type, the oral segment accounted for the highest share in 2024 owing to the easy administration and wide availability of orally administered NSAIDs products in the market
  • Based on the distribution channel, retail pharmacies are expected to dominate the market with a 54.39% share in 2024. This dominance can be attributed to the presence of a large number of generic NSAIDs and their easy accessibility to patients due to the large presence of retail pharmacies network
  • Asia Pacific region is expected to experience the fastest growth during the forecast period owing to an increase in penetration of NSAIDs products, rise in disposable income, and high disease prevalence of inflammatory diseases in developing countries

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Pain
    • 1.2.3. Route of Administration
    • 1.2.4. Distribution channel
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug class and pain outlook
    • 2.2.2. Route of administration and distribution channel outlook
  • 2.3. Competitive Insights

Chapter 3. Non-opioid Pain Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. High prevalence of chronic & inflammatory diseases globally
      • 3.2.1.2. Increasing product approvals and launches
      • 3.2.1.3. Supportive regulatory and reimbursement policies
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Stringent regulations
      • 3.2.2.2. Side-effects associated with drug
  • 3.3. Non-opioid Pain Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. Pricing Analysis

Chapter 4. Non-opioid Pain Treatment Market: Drug Class Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Non-opioid Pain Treatment Market: Drug Class Movement Analysis
  • 4.3. Global Non-opioid Pain Treatment Market Estimates and Forecasts, By Drug, Class Revenue (USD Million)
  • 4.4. NSAIDs
    • 4.4.1. NSAIDs market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Non-Selective NSAIDs
      • 4.4.2.1. Non-Selective NSAIDs market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Selective COX-2 Inhibitors
      • 4.4.3.1. Selective COX-2 Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Acetaminophen
    • 4.5.1. Acetaminophen market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Local Anesthetics
    • 4.6.1. Local Anesthetics market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Other Drug Class
    • 4.7.1. Others drug class market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Non-opioid Pain Treatment Market: Pain Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Non-opioid Pain Treatment Market: Pain Movement Analysis
  • 5.3. Global Non-opioid Pain Treatment Market Estimates and Forecasts, By Pain, Revenue (USD Million)
  • 5.4. Post-operative Pain
    • 5.4.1. Post-operative pain market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Cancer Pain
    • 5.5.1. Cancer pain market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Chronic Pain
    • 5.6.1. Chronic pain market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Other Pain
    • 5.7.1. Other pain market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Non-opioid Pain Treatment Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Non-opioid Pain Treatment Market: Route of Administration Movement Analysis
  • 6.3. Global Non-opioid Pain Treatment Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
  • 6.4. Oral
    • 6.4.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Topical
    • 6.5.1. Topical market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Injectable
    • 6.6.1. Injectable market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Other Route of Administration
    • 6.7.1. Other route of administration market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Non-opioid Pain Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Non-opioid Pain Treatment Market: Distribution Channel Movement Analysis
  • 7.3. Global Non-opioid Pain Treatment Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
  • 7.4. Hospitals Pharmacies
    • 7.4.1. Hospitals pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Online Pharmacies
    • 7.6.1. Online Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Non-opioid Pain Treatment Market: Regional Estimates & Trend Analysis By Drug Clas, Pain, Route of Administration, and Distribution Channel

  • 8.1. Regional Dashboard
  • 8.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 8.3. North America
    • 8.3.1. U.S.
      • 8.3.1.1. Key country dynamics
      • 8.3.1.2. Regulatory framework/ reimbursement structure
      • 8.3.1.3. Competitive scenario
      • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.2. Canada
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Regulatory framework/ reimbursement structure
      • 8.3.2.3. Competitive scenario
      • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.3. Mexico
      • 8.3.3.1. Key country dynamics
      • 8.3.3.2. Regulatory framework/ reimbursement structure
      • 8.3.3.3. Competitive scenario
      • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.4. Italy
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.5. Spain
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Regulatory framework/ reimbursement structure
      • 8.4.5.3. Competitive scenario
      • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.6. Norway
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Regulatory framework/ reimbursement structure
      • 8.4.6.3. Competitive scenario
      • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Regulatory framework/ reimbursement structure
      • 8.4.7.3. Competitive scenario
      • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.8. Denmark
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Regulatory framework/ reimbursement structure
      • 8.4.8.3. Competitive scenario
      • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. China
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. India
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. Australia
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.5. South Korea
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Argentina
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. Key company market share analysis, 2024
    • 9.3.2. Novartis AG
      • 9.3.2.1. Company overview
      • 9.3.2.2. Financial performance
      • 9.3.2.3. Product benchmarking
      • 9.3.2.4. Strategic initiatives
    • 9.3.3. Teva Pharmaceutical Industries Limited
      • 9.3.3.1. Company overview
      • 9.3.3.2. Financial performance
      • 9.3.3.3. Product benchmarking
      • 9.3.3.4. Strategic initiatives
    • 9.3.4. Teva Pharmaceutical Industries Limited
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Sun Pharmaceutical Industries Ltd
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. GSK plc.
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Pfizer Inc.
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Perrigo Company plc.
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. LNK International, Inc.
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Cipla Inc.
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Johnson & Johnson Services, Inc.
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Pacira Pharmaceuticals, Inc.
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Pierrel
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Product benchmarking
      • 9.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations
  • Table 3 List of key distributors
  • Table 4 List of other companies
  • Table 5 List of key emerging company's/technology disruptors/innovators
  • Table 6 North America Non-Opioid Pain Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 7 North America Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 8 North America Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 9 North America Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 10 North America Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 U.S. Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 12 U.S. Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 13 U.S. Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 14 U.S. Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 15 Canada Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 16 Canada Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 17 Canada Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 18 Canada Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 Mexico Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 20 Mexico Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 21 Mexico Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 22 Mexico Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 Europe Non-Opioid Pain Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 24 Europe Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 25 Europe Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 26 Europe Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 27 Europe Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 28 UK Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 29 UK Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 30 UK Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 31 UK Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Germany Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 33 Germany Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 34 Germany Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 35 Germany Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 France Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 37 France Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 38 France Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 39 France Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 Spain Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 41 Spain Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 42 Spain Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 43 Spain Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Italy Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 45 Italy Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 46 Italy Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 47 Italy Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 48 Denmark Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 49 Denmark Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 50 Denmark Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 51 Denmark Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 Sweden Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 53 Sweden Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 54 Sweden Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 55 Sweden Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56 Norway Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 57 Norway Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 58 Norway Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 59 Norway Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 63 Asia Pacific Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 64 Japan Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 65 Japan Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 66 Japan Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 67 Japan Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 68 China Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 69 China Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 70 China Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 71 China Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 72 India Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 73 India Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 74 India Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 75 India Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 76 Australia Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 77 Australia Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 78 Australia Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 79 Australia Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 80 South Korea Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 81 South Korea Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 82 South Korea Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 83 South Korea Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 84 Thailand Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 85 Thailand Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 86 Thailand Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 87 Thailand Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 88 Latin America Non-Opioid Pain Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 89 Latin America Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 90 Latin America Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 91 Latin America Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 92 Latin America Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 93 Brazil Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 94 Brazil Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 95 Brazil Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 96 Brazil Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 97 Argentina Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 98 Argentina Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 99 Argentina Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 100 Argentina Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 101 MEA Non-Opioid Pain Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 102 MEA Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 103 MEA Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 104 MEA Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 105 MEA Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 106 South Africa Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 107 South Africa Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 108 South Africa Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 109 South Africa Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 111 Saudi Arabia Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 112 Saudi Arabia Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 114 UAE Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 115 UAE Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 116 UAE Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 117 UAE Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 118 Kuwait Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 119 Kuwait Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 120 Kuwait Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 121 Kuwait Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Non-opioid pain treatment market Segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Non- opioid pain treatment market snapshot
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook, revenue, 2024 (USD Million)
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Non- opioid pain treatment market driver impact
  • Fig. 14 Non- opioid pain treatment market restraint impact
  • Fig. 15 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 16 Industry Analysis - Porter's Five Forces
  • Fig. 17 Strategy mapping
  • Fig. 18 Non-opioid pain treatment market: Drug class outlook and key takeaways
  • Fig. 19 Non- opioid pain treatment market: Drug class movement analysis & market share 2024 & 2030
  • Fig. 20 NSAIDs non-opioid treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Non-selective NSAIDs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Selective COX-2 inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Acetaminophen market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Local Anesthetics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Other drug class market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Non-opioid treatment market: Pain outlook and key takeaways
  • Fig. 27 Non-opioid treatment market: Pain movement analysis & market share 2024 & 2030
  • Fig. 28 Post-operative pain market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Cancer pain market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Chronic pain market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Other pain non-opioid treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Non- non-opioid treatment market: Distribution channel outlook and key takeaways
  • Fig. 33 Non- non-opioid treatment market: Distribution channel movement analysis & market share 2024 & 2030
  • Fig. 34 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Global Non-opioid Pain Treatment market: Regional movement analysis
  • Fig. 38 Global Non-opioid Pain Treatment market: Regional outlook and key takeaways
  • Fig. 39 Global Non-opioid Pain Treatment market share and leading players
  • Fig. 40 North America, by country
  • Fig. 41 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 U.S. key country dynamics
  • Fig. 43 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Canada key country dynamics
  • Fig. 45 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Mexico key country dynamics
  • Fig. 47 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 UK key country dynamics
  • Fig. 50 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Germany key country dynamics
  • Fig. 52 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 France key country dynamics
  • Fig. 54 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Italy key country dynamics
  • Fig. 56 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Spain key country dynamics
  • Fig. 58 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Denmark key country dynamics
  • Fig. 60 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Sweden key country dynamics
  • Fig. 62 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Norway key country dynamics
  • Fig. 64 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 China key country dynamics
  • Fig. 67 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Japan key country dynamics
  • Fig. 69 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 India key country dynamics
  • Fig. 71 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Thailand key country dynamics
  • Fig. 73 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 South Korea key country dynamics
  • Fig. 75 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Australia key country dynamics
  • Fig. 77 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Brazil key country dynamics
  • Fig. 80 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Argentina key country dynamics
  • Fig. 82 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 South Africa key country dynamics
  • Fig. 85 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Saudi Arabia key country dynamics
  • Fig. 87 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 UAE key country dynamics
  • Fig. 89 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Kuwait key country dynamics
  • Fig. 91 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Market share Analysis of key market players, 2024